183 related articles for article (PubMed ID: 9351541)
1. Low serum levels of soluble CD44 variant 6 are significantly associated with poor prognosis in patients with pancreatic carcinoma.
Gansauge F; Gansauge S; Rau B; Scheiblich A; Poch B; Schoenberg MH; Beger HG
Cancer; 1997 Nov; 80(9):1733-9. PubMed ID: 9351541
[TBL] [Abstract][Full Text] [Related]
2. Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer.
Yamane N; Tsujitani S; Makino M; Maeta M; Kaibara N
Oncology; 1999 Apr; 56(3):232-8. PubMed ID: 10202279
[TBL] [Abstract][Full Text] [Related]
3. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma.
Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
Cancer; 1998 Sep; 83(6):1094-101. PubMed ID: 9740073
[TBL] [Abstract][Full Text] [Related]
4. CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients.
Li Z; Chen K; Jiang P; Zhang X; Li X; Li Z
Diagn Pathol; 2014 Apr; 9():79. PubMed ID: 24708709
[TBL] [Abstract][Full Text] [Related]
5. CD44 variant overexpression in gallbladder carcinoma associated with tumor dedifferentiation.
Yanagisawa N; Mikami T; Mitomi H; Saegusa M; Koike M; Okayasu I
Cancer; 2001 Jan; 91(2):408-16. PubMed ID: 11180088
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis.
Amirghofran Z; Jalali SA; Hosseini SV; Vasei M; Sabayan B; Ghaderi A
J Gastrointest Cancer; 2008; 39(1-4):73-8. PubMed ID: 19333790
[TBL] [Abstract][Full Text] [Related]
7. Correlation of CD44v6 expression with ovarian cancer progression and recurrence.
Shi J; Zhou Z; Di W; Li N
BMC Cancer; 2013 Apr; 13():182. PubMed ID: 23565736
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas.
Berner HS; Suo Z; Risberg B; Villman K; Karlsson MG; Nesland JM
Histopathology; 2003 Jun; 42(6):546-54. PubMed ID: 12786890
[TBL] [Abstract][Full Text] [Related]
11. Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma.
Harn HJ; Ho LI; Shyu RY; Yuan JS; Lin FG; Young TH; Liu CA; Tang HS; Lee WH
J Clin Gastroenterol; 1996 Mar; 22(2):107-10. PubMed ID: 8742647
[TBL] [Abstract][Full Text] [Related]
12. Soluble CD44 and CD44v6 and prognosis in children with B-cell acute lymphoblastic leukemia.
Amirghofran Z; Asiaee E; Kamazani FM
Asia Pac J Clin Oncol; 2016 Sep; 12(3):e375-82. PubMed ID: 25227983
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD44v6 and integrin-β1 for the prognosis evaluation of pancreatic cancer patients after cryosurgery.
Zhou G; Chiu D; Qin D; Niu L; Cai J; He L; Tan D; Xu K
Diagn Pathol; 2013 Sep; 8():146. PubMed ID: 24004467
[TBL] [Abstract][Full Text] [Related]
14. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
[TBL] [Abstract][Full Text] [Related]
15. Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer.
Aaltomaa S; Lipponen P; Ala-Opas M; Kosma VM
Eur Urol; 2001 Feb; 39(2):138-44. PubMed ID: 11223672
[TBL] [Abstract][Full Text] [Related]
16. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
Afify A; Lynne LC; Howell L
Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD44 variant isoforms and association to the benign form of endocrine pancreatic tumours.
Imam H; Eriksson B; Oberg K
Ann Oncol; 2000 Mar; 11(3):295-300. PubMed ID: 10811495
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis.
Ropponen KM; Eskelinen MJ; Lipponen PK; Alhava E; Kosma VM
Scand J Gastroenterol; 1998 Mar; 33(3):301-9. PubMed ID: 9548625
[TBL] [Abstract][Full Text] [Related]
19. Serological evaluation of soluble CD44 in renal cancer.
Kan M; Kanayama H; Naruo S; Tsuji M; Kojima K; Kurokawa Y; Kagawa S
Jpn J Cancer Res; 1996 Nov; 87(11):1191-4. PubMed ID: 9045950
[TBL] [Abstract][Full Text] [Related]
20. Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients.
Mayer S; zur Hausen A; Watermann DO; Stamm S; Jäger M; Gitsch G; Stickeler E
J Cancer Res Clin Oncol; 2008 Nov; 134(11):1229-35. PubMed ID: 18438684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
